Fig 1: Specificity of SLC43A2 and SLC7A5 shRNA.(A) Transcript levels of SLC43A2 or SLC7A5 genes in NIH3T3 cell line transfected with shRNA to SLC43A2, relative to the cells transfected with scrambled control and cultured for 48 h in complete medium. Data shown is mean ± SD of two independent experiments. (B, C) Immunoblots probed for SLC43A2 (B), SLC7A5 (C), or tubulin in whole-cell lysates from WT Tregs transduced with retroviruses containing shRNA to SLC43A2 (panel B), SLC7A5 (panel C) or scrambled control. Immunoblots are representative of two independent experiments. (D) Immunoblots probed for SLC43A2 or actin in whole-cell lysates from WT Tregs transduced with retroviruses shRNA to SLC43A2 or scrambled control. Immunoblots are representative of two independent experiments. (Ei) Representative images of Tregs immune-stained for Foxp3 in WT Tregs transduced with shRNA to SLC43A2 or scrambled control. Scale bar: 5 μm. Images are representative of at least 100 cells. (Eii) Percentage of Foxp3+ cells in WT Tregs transduced with shRNA to SLC43A2 or scrambled control.Source data are available for this figure.
Fig 2: Notch-dependent SLC43A2 transporter regulates methionine-dependent Tregs survival.(A) SLC43A2 and not SLC7A5 is required for Tregs survival: indicated are the percentage of cells with apoptotic nuclei in WT Tregs transduced with retroviruses containing shRNA to SCL43A2, SLC7A5, or scrambled control and cultured without IL-2 for 18–22 h. Also, see Fig S4A–C for shRNA-based knockdown efficacy and specificity. (B) SLC43A2 is required for methionine-dependent Treg survival: percentage of cells with apoptotic nuclei in WT Tregs transduced with retroviruses containing shRNA to SLC43A2 or scrambled control and cultured in complete medium with dialyzed serum (CMDS) or dropout of sulfur amino acids (DOSAA) with (150 μM) or without methionine for 18–22 h. Also, see Fig S4D for knockdown efficacy and Fig S4E for Foxp3 expression. (C) Notch1 dependence of SLC43A2 or SLC7A5 in activated Tregs: immunoblots of cell lysates prepared from activated Notch1−/− (Cre+ve; Cd4-Cre::Notch1lox/lox) and Notch1+/+ (Cre−ve) Tregs probed for (i) SLC43A2, Notch1, and (ii) SLC7A5 (actin control). The cell lysate was split and used for C-i and C-ii. Inset: densitometry based fold change in the protein levels of SLC43A2 and SLC7A5 in Notch1−/− Tregs relative to Notch1+/+ Tregs. Data indicate mean ± SD of three independent experiments for C-i and two independent experiments for C-ii. Also, see Fig S5A and B showing steady-state SLC43A2 protein in Tregs and SLC43A2 or SLC7A5 protein in Teffs, in Notch1−/− versus Notch1+/+. See Fig S5C for SLC43A2 and SLC7A5 protein in Tregs treated with the Notch1 inhibitor GSI-X. (D) SLC43A2 and SLC7A5 and Notch1 in freshly isolated Tregs: immunoblots probed for SLC43A2, Notch1 (tubulin loading control) in freshly isolated Notch1+/+ and Notch1−/− Tregs. Inset: densitometric analysis indicating fold change in the protein levels of SLC43A2 in freshly isolated Notch1+/+ and Notch1−/− Tregs. (E) Cytoplasmic Notch1 dependence: Immunoblots probed for SLC43A2, Notch1 (actin control) in Notch1−/− Tregs transduced with retroviruses containing pBABE-NIC-NES, or control pBABE plasmid (immunoblots are representative of three independent experiments). Inset: densitometry based fold change in the protein levels of SLC43A2 in Notch1−/− Tregs transduced with pBABE-NIC-NES relative to control pBABE. (F) Sufficiency of SLC43A2 for Tregs survival: indicated are the percentage of cells with apoptotic nuclei in Notch1−/− (Cre+ve; Cd4-Cre::Notch1lox/lox) Tregs transduced with retroviruses containing pBABE-NIC-NES, pBABE-SLC43A2, or control pBABE plasmid and cultured without IL-2 for 18–22 h. Also, see Fig S5D for Notch1 and SLC43A2 protein levels in these conditions. (G) Model for methionine requirements for Tregs survival: Upon IL-2 depletion, Tregs continuously take up and use methionine for survival. This occurs through the SLC43A2 transporter in a Notch1-dependent manner. Notch1 regulates SLC43A2 expression, and this transporter allows Tregs to take up methionine, and use it, enabling Tregs survival. (A, B, D, E, F) Data indicate mean ± SD of two independent experiments in panels (B) and (F) and three independent experiments in panels (A), (D), and (E). ***P ≤ 0.001, **P ≤ 0.01, *P ≤ 0.05, ns implies nonsignificant.Source data are available for this figure.
Fig 3: Comparison of Notch1 dependence of SLC43A2 in Tregs and Teffs.(A) Immunoblots of cell lysates prepared from activated Notch1−/− (Cre+ve; Cd4-Cre::Notch1lox/lox) and Notch1+/+ (Cre−ve) Tregs at T0 or cultured without IL-2 for 4 h, probed for Notch1, SLC43A2, and actin. (B) Immunoblots of cell lysates prepared from activated Notch1−/− (Cre+ve; Cd4-Cre::Notch1lox/lox) and Notch1+/+ (Cre−ve) Teffs, which were split to probe for SLC43A2, Notch1, and tubulin and SLC7A5 and actin. Immunoblots are representative of two independent experiments. (C) Immunoblots probed for Notch1, actin, and SLC43A2 (i) or SLC7A5 (ii) in whole-cell lysates from WT Tregs cultured with GSI-X (10 μM) in the complete medium without IL-2 for 7 h. (D) Immunoblots probed for Notch1 (tubulin control) and SLC43A2 (actin control) in Notch1−/− Tregs transduced with retroviruses containing pBABE-NIC-NES, pBABE-SLC43A2, or control pBABE plasmid. Immunoblots are representative of two independent experiments.Source data are available for this figure.
Supplier Page from OriGene Technologies for Slc7a5 Mouse shRNA Plasmid (Locus ID 20539)